Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease
Abstract Background Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcope...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Medical Directors Association 2016-08, Vol.17 (8), p.712-718 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 718 |
|---|---|
| container_issue | 8 |
| container_start_page | 712 |
| container_title | Journal of the American Medical Directors Association |
| container_volume | 17 |
| creator | Joppa, Pavol, MD, PhD Tkacova, Ruzena, MD, PhD Franssen, Frits M.E., MD, PhD Hanson, Corrine, PhD Rennard, Stephen I., MD Silverman, Edwin K., MD, PhD McDonald, Merry-Lynn N., PhD Calverley, Peter M.A., MD, FRCP Tal-Singer, Ruth, PhD Spruit, Martijn A., PhD Kenn, Klaus, MD Wouters, Emiel F.M., MD, PhD Rutten, Erica P.A., PhD |
| description | Abstract Background Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0–5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (−28.0 m, 95% CI −45.6 to −10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1–2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. Trial registry ClinicalTrials.gov no. NCT00292552. |
| doi_str_mv | 10.1016/j.jamda.2016.03.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1807894472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1525861016300603</els_id><sourcerecordid>1807894472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-2e40832cabba43c33b904076cd33a64ee80d22f370cd091a5e38fb9b1bc2ed8a3</originalsourceid><addsrcrecordid>eNqFkc9u1DAQhyNERf_AEyAhHzk06djOJs4BJLS0UKnSVloQR8uxJ6pDnCy2U2l5Gp6FJ8NhWw69cPJY-uZnzzdZ9ppCQYFWF33RK2dUwdKlAF4Ag2fZCV1xkTe8Xj1farbKRUXhODsNoYdE0KZ6kR2zmlZUlOIk-7lVXk87HK0mmxaDjftzcjWPOtppVAPZzFFPDsM5UaMh232I6BJ6PXaDck4tFLEjuU0VjjGQbzbekfWdnw6BIfo5Rd0juZ0HlxL9_vevjzagCvgyO-rUEPDVw3mWfb26_LL-nN9sPl2vP9zkuqRlzBmWIDjTqm1VyTXnbQMl1JU2nKuqRBRgGOt4DdpAQ9UKuejapqWtZmiE4mfZ20Puzk8_ZgxROhs0DoMacZqDpAJq0ZRlzRLKD6j2UwgeO7nz1qVPSwpykS57-Ve6XKRL4DIpTV1vHh6YW4fmX8-j5QS8OwCYxry36GXQSZdGYz3qKM1k__PA-yf9erBJsBq-4x5DP80-7SpNIgOTILfL3pe104oDVMD5H9HDq28</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807894472</pqid></control><display><type>article</type><title>Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Joppa, Pavol, MD, PhD ; Tkacova, Ruzena, MD, PhD ; Franssen, Frits M.E., MD, PhD ; Hanson, Corrine, PhD ; Rennard, Stephen I., MD ; Silverman, Edwin K., MD, PhD ; McDonald, Merry-Lynn N., PhD ; Calverley, Peter M.A., MD, FRCP ; Tal-Singer, Ruth, PhD ; Spruit, Martijn A., PhD ; Kenn, Klaus, MD ; Wouters, Emiel F.M., MD, PhD ; Rutten, Erica P.A., PhD</creator><creatorcontrib>Joppa, Pavol, MD, PhD ; Tkacova, Ruzena, MD, PhD ; Franssen, Frits M.E., MD, PhD ; Hanson, Corrine, PhD ; Rennard, Stephen I., MD ; Silverman, Edwin K., MD, PhD ; McDonald, Merry-Lynn N., PhD ; Calverley, Peter M.A., MD, FRCP ; Tal-Singer, Ruth, PhD ; Spruit, Martijn A., PhD ; Kenn, Klaus, MD ; Wouters, Emiel F.M., MD, PhD ; Rutten, Erica P.A., PhD</creatorcontrib><description>Abstract Background Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0–5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (−28.0 m, 95% CI −45.6 to −10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1–2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. Trial registry ClinicalTrials.gov no. NCT00292552.</description><identifier>ISSN: 1525-8610</identifier><identifier>EISSN: 1538-9375</identifier><identifier>DOI: 10.1016/j.jamda.2016.03.020</identifier><identifier>PMID: 27161848</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>6-minute walking distance ; Aged ; Body composition ; chronic obstructive pulmonary disease ; Comorbidity ; Female ; fibrinogen ; Health Status ; Humans ; Inflammation ; Internal Medicine ; Longitudinal Studies ; Male ; Medical Education ; Middle Aged ; Multicenter Studies as Topic ; Obesity ; Observational Studies as Topic ; Pulmonary Disease, Chronic Obstructive ; Sarcopenia ; sarcopenic obesity ; systemic inflammation</subject><ispartof>Journal of the American Medical Directors Association, 2016-08, Vol.17 (8), p.712-718</ispartof><rights>AMDA - The Society for Post-Acute and Long-Term Care Medicine</rights><rights>2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine</rights><rights>Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-2e40832cabba43c33b904076cd33a64ee80d22f370cd091a5e38fb9b1bc2ed8a3</citedby><cites>FETCH-LOGICAL-c414t-2e40832cabba43c33b904076cd33a64ee80d22f370cd091a5e38fb9b1bc2ed8a3</cites><orcidid>0000-0001-5055-0682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1525861016300603$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27161848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joppa, Pavol, MD, PhD</creatorcontrib><creatorcontrib>Tkacova, Ruzena, MD, PhD</creatorcontrib><creatorcontrib>Franssen, Frits M.E., MD, PhD</creatorcontrib><creatorcontrib>Hanson, Corrine, PhD</creatorcontrib><creatorcontrib>Rennard, Stephen I., MD</creatorcontrib><creatorcontrib>Silverman, Edwin K., MD, PhD</creatorcontrib><creatorcontrib>McDonald, Merry-Lynn N., PhD</creatorcontrib><creatorcontrib>Calverley, Peter M.A., MD, FRCP</creatorcontrib><creatorcontrib>Tal-Singer, Ruth, PhD</creatorcontrib><creatorcontrib>Spruit, Martijn A., PhD</creatorcontrib><creatorcontrib>Kenn, Klaus, MD</creatorcontrib><creatorcontrib>Wouters, Emiel F.M., MD, PhD</creatorcontrib><creatorcontrib>Rutten, Erica P.A., PhD</creatorcontrib><title>Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease</title><title>Journal of the American Medical Directors Association</title><addtitle>J Am Med Dir Assoc</addtitle><description>Abstract Background Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0–5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (−28.0 m, 95% CI −45.6 to −10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1–2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. Trial registry ClinicalTrials.gov no. NCT00292552.</description><subject>6-minute walking distance</subject><subject>Aged</subject><subject>Body composition</subject><subject>chronic obstructive pulmonary disease</subject><subject>Comorbidity</subject><subject>Female</subject><subject>fibrinogen</subject><subject>Health Status</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Internal Medicine</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical Education</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Obesity</subject><subject>Observational Studies as Topic</subject><subject>Pulmonary Disease, Chronic Obstructive</subject><subject>Sarcopenia</subject><subject>sarcopenic obesity</subject><subject>systemic inflammation</subject><issn>1525-8610</issn><issn>1538-9375</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQhyNERf_AEyAhHzk06djOJs4BJLS0UKnSVloQR8uxJ6pDnCy2U2l5Gp6FJ8NhWw69cPJY-uZnzzdZ9ppCQYFWF33RK2dUwdKlAF4Ag2fZCV1xkTe8Xj1farbKRUXhODsNoYdE0KZ6kR2zmlZUlOIk-7lVXk87HK0mmxaDjftzcjWPOtppVAPZzFFPDsM5UaMh232I6BJ6PXaDck4tFLEjuU0VjjGQbzbekfWdnw6BIfo5Rd0juZ0HlxL9_vevjzagCvgyO-rUEPDVw3mWfb26_LL-nN9sPl2vP9zkuqRlzBmWIDjTqm1VyTXnbQMl1JU2nKuqRBRgGOt4DdpAQ9UKuejapqWtZmiE4mfZ20Puzk8_ZgxROhs0DoMacZqDpAJq0ZRlzRLKD6j2UwgeO7nz1qVPSwpykS57-Ve6XKRL4DIpTV1vHh6YW4fmX8-j5QS8OwCYxry36GXQSZdGYz3qKM1k__PA-yf9erBJsBq-4x5DP80-7SpNIgOTILfL3pe104oDVMD5H9HDq28</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Joppa, Pavol, MD, PhD</creator><creator>Tkacova, Ruzena, MD, PhD</creator><creator>Franssen, Frits M.E., MD, PhD</creator><creator>Hanson, Corrine, PhD</creator><creator>Rennard, Stephen I., MD</creator><creator>Silverman, Edwin K., MD, PhD</creator><creator>McDonald, Merry-Lynn N., PhD</creator><creator>Calverley, Peter M.A., MD, FRCP</creator><creator>Tal-Singer, Ruth, PhD</creator><creator>Spruit, Martijn A., PhD</creator><creator>Kenn, Klaus, MD</creator><creator>Wouters, Emiel F.M., MD, PhD</creator><creator>Rutten, Erica P.A., PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5055-0682</orcidid></search><sort><creationdate>20160801</creationdate><title>Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease</title><author>Joppa, Pavol, MD, PhD ; Tkacova, Ruzena, MD, PhD ; Franssen, Frits M.E., MD, PhD ; Hanson, Corrine, PhD ; Rennard, Stephen I., MD ; Silverman, Edwin K., MD, PhD ; McDonald, Merry-Lynn N., PhD ; Calverley, Peter M.A., MD, FRCP ; Tal-Singer, Ruth, PhD ; Spruit, Martijn A., PhD ; Kenn, Klaus, MD ; Wouters, Emiel F.M., MD, PhD ; Rutten, Erica P.A., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-2e40832cabba43c33b904076cd33a64ee80d22f370cd091a5e38fb9b1bc2ed8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>6-minute walking distance</topic><topic>Aged</topic><topic>Body composition</topic><topic>chronic obstructive pulmonary disease</topic><topic>Comorbidity</topic><topic>Female</topic><topic>fibrinogen</topic><topic>Health Status</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Internal Medicine</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical Education</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Obesity</topic><topic>Observational Studies as Topic</topic><topic>Pulmonary Disease, Chronic Obstructive</topic><topic>Sarcopenia</topic><topic>sarcopenic obesity</topic><topic>systemic inflammation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joppa, Pavol, MD, PhD</creatorcontrib><creatorcontrib>Tkacova, Ruzena, MD, PhD</creatorcontrib><creatorcontrib>Franssen, Frits M.E., MD, PhD</creatorcontrib><creatorcontrib>Hanson, Corrine, PhD</creatorcontrib><creatorcontrib>Rennard, Stephen I., MD</creatorcontrib><creatorcontrib>Silverman, Edwin K., MD, PhD</creatorcontrib><creatorcontrib>McDonald, Merry-Lynn N., PhD</creatorcontrib><creatorcontrib>Calverley, Peter M.A., MD, FRCP</creatorcontrib><creatorcontrib>Tal-Singer, Ruth, PhD</creatorcontrib><creatorcontrib>Spruit, Martijn A., PhD</creatorcontrib><creatorcontrib>Kenn, Klaus, MD</creatorcontrib><creatorcontrib>Wouters, Emiel F.M., MD, PhD</creatorcontrib><creatorcontrib>Rutten, Erica P.A., PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Medical Directors Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joppa, Pavol, MD, PhD</au><au>Tkacova, Ruzena, MD, PhD</au><au>Franssen, Frits M.E., MD, PhD</au><au>Hanson, Corrine, PhD</au><au>Rennard, Stephen I., MD</au><au>Silverman, Edwin K., MD, PhD</au><au>McDonald, Merry-Lynn N., PhD</au><au>Calverley, Peter M.A., MD, FRCP</au><au>Tal-Singer, Ruth, PhD</au><au>Spruit, Martijn A., PhD</au><au>Kenn, Klaus, MD</au><au>Wouters, Emiel F.M., MD, PhD</au><au>Rutten, Erica P.A., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease</atitle><jtitle>Journal of the American Medical Directors Association</jtitle><addtitle>J Am Med Dir Assoc</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>17</volume><issue>8</issue><spage>712</spage><epage>718</epage><pages>712-718</pages><issn>1525-8610</issn><eissn>1538-9375</eissn><abstract>Abstract Background Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0–5.4, P < .001). In patients with COPD, SO was related to reduced 6-minute walking distance (−28.0 m, 95% CI −45.6 to −10.4), P < .01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1–2.5, P = .028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. Trial registry ClinicalTrials.gov no. NCT00292552.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27161848</pmid><doi>10.1016/j.jamda.2016.03.020</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5055-0682</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-8610 |
| ispartof | Journal of the American Medical Directors Association, 2016-08, Vol.17 (8), p.712-718 |
| issn | 1525-8610 1538-9375 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1807894472 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | 6-minute walking distance Aged Body composition chronic obstructive pulmonary disease Comorbidity Female fibrinogen Health Status Humans Inflammation Internal Medicine Longitudinal Studies Male Medical Education Middle Aged Multicenter Studies as Topic Obesity Observational Studies as Topic Pulmonary Disease, Chronic Obstructive Sarcopenia sarcopenic obesity systemic inflammation |
| title | Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T08%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sarcopenic%20Obesity,%20Functional%20Outcomes,%20and%20Systemic%20Inflammation%20in%20Patients%20With%20Chronic%20Obstructive%20Pulmonary%C2%A0Disease&rft.jtitle=Journal%20of%20the%20American%20Medical%20Directors%20Association&rft.au=Joppa,%20Pavol,%20MD,%20PhD&rft.date=2016-08-01&rft.volume=17&rft.issue=8&rft.spage=712&rft.epage=718&rft.pages=712-718&rft.issn=1525-8610&rft.eissn=1538-9375&rft_id=info:doi/10.1016/j.jamda.2016.03.020&rft_dat=%3Cproquest_cross%3E1807894472%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807894472&rft_id=info:pmid/27161848&rft_els_id=1_s2_0_S1525861016300603&rfr_iscdi=true |